Koninklijke Philips N.V. (PHG) Q2 2025 Earnings Call Transcript

Koninklijke Philips delivered solid Q2 2025 results, reporting 6% order intake growth and 1% comparable sales increase, largely driven by strong Personal Health performance. Adjusted EBITA margin expanded 130 basis points to 12.4%, reflecting innovation and productivity measures. Consequently, Philips reiterated its full-year comparable sales growth outlook of 1-3% while raising its adjusted EBITA margin forecast to 11.3-11.8% and free cash flow to EUR 0.2-0.4 billion, incorporating revised tariff impacts and strong order momentum. The company is well-positioned for accelerated growth in the second half, underpinned by a robust order book and successful innovation uptake, targeting mid-single-digit growth and mid-teens margins beyond 2025.

Analysis

Koninklijke Philips N.V. reported a resilient Q2 2025, characterized by robust order intake and margin expansion despite modest top-line growth. Comparable sales increased 1%, with strong performance in the Personal Health segment offsetting slight declines in Diagnosis & Treatment (D&T) and Connected Care, which faced high prior-year comparison bases. The company's future revenue visibility has strengthened, evidenced by a 6% growth in order intake, building on a 9% increase in the prior year, and a 7% year-over-year expansion of the total order book. This momentum is fueled by strong demand for new high-margin innovations, such as the helium-free BlueSeal MRI systems, which now constitute all 1.5T MRI orders, and the AI-enabled CT 5300. Operationally, Philips demonstrated strong execution, delivering EUR 197 million in productivity savings and improving service levels to a record 86%. This operational discipline, combined with a favorable revision in tariff impact estimates, prompted an upgrade to full-year guidance. While the 1-3% comparable sales growth forecast was reiterated, the adjusted EBITA margin range was increased by 50 basis points to 11.3%-11.8%, and the free cash flow outlook was raised to between EUR 0.2 billion and EUR 0.4 billion. Management remains cautious on the China recovery but noted the completion of its Personal Health destocking program in the region, setting the stage for an improved second-half performance.

Key Decisions for Investors

• Investors should focus on the guided second-half acceleration, as the 7% year-over-year growth in the order book provides strong visibility for sales conversion and underpins the company's confidence in meeting its full-year targets.
• While the Q2 adjusted EBITA margin expansion of 130 basis points is a positive indicator, it is critical to anticipate the guided year-over-year margin decline in Q3 due to the timing of tariff impacts before a projected rebound in Q4.
• The success of the turnaround is heavily dependent on the continued market adoption of new, higher-margin innovations; therefore, monitor order momentum for key products like BlueSeal MRI, Spectral CT, and the Azurion platform as a primary indicator of sustainable profitable growth.
• Consider the China market as a potential source of upside, as management's cautious outlook may not fully capture a faster-than-expected recovery now that the Personal Health destocking is complete and medical equipment tenders are slowly increasing.